Top 20 Cancer Therapy Brands in Australia Forecast

Published by: Datamonitor

Published: Mar. 1, 2010 - 35 Pages


Table of Contents


Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Abstract

Introduction

The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% since 2005. Datamonitor forecasts this growth to slow down considerably to a CAGR of 5.6% between 2008 and 2018 mainly due to maturing markets and the entry of generics for several key products. Sales of the Top 20 brands are expected to reach a total of $940m in 2018.

Reasons to Purchase
  • Identify key opportunities and threats that will impact the Australian oncology market as a whole and the Top 20 in particular
  • Quantify the future size and scope of the Top 20 Australian cancer therapies market and predict the performance of its key compounds
  • Understand critical success factors in growing and defending cancer brand franchises from new entrants and generics
Please note: this is delivered as a Zip file.

Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.